CClinicalTrials.gg
SuspendedNCT03434366Updated Apr 12, 2022

Intranasal Ketamine With Dexmedetomidine for the Treatment of Children With Autism Spectrum Disorder

A Phase 2 interventional study of ketamine and dexmedetomidine and ketamine in Autism Spectrum Disorder, sponsored by Guangzhou Women and Children's Medical Center. Suspended at 1 site in China. Open to participants aged 2 Years to 15 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-12.

Sponsored by Guangzhou Women and Children's Medical Center · Phase 2, Interventional, and Treatment

Why this study was suspended
The effects are not good
Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
2 Years to 15 Years
Sex
All
01

Study summary

Autism spectrum disorder (ASD) is a life-long neurodevelopmental disorder characterized by qualitative abnormalities in reciprocal social interactions and patterns of communication, and by a restricted, stereotyped, repetitive repertoire of interests and activities. The use of medications in adolescents and young adults with ASD is extremely common. However, few data address the effectiveness and harms of medications specifically in this population.

The purpose of the study is to determine the efficacy and safety of intranasal ketamine with dexmedetomidine in children with ASD.

Read the detailed description

The use of medications in adolescents and young adults with ASD is extremely common. few data address the effectiveness and harms of medications specifically in this population. A previous study reported the first case study demonstrating clinical improvement in mood and eye fixation scores from intranasal ketamine treatment in a "complicated" subject with autism spectrum disorderHowever,The purpose of the study is to determine the efficacy and safety of intranasal ketamine with dexmedetomidine in children with ASD.

02

Conditions studied

  • Autism Spectrum Disorder

Keywords

  • Autism Spectrum Disorder
  • ketamine
  • dexmedetomidine
03

Who can participate

Ages eligible
2 Years to 15 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. meet autism diagnostic criteria based on DSM-5/ADI-R/ADOS
  2. children aged 2 years through 15 years of age
  3. parents/guardians can cooperate with the study and sign informed consent
  4. ASA score I or II

Exclusion criteria

Exclusion Criteria:

  1. with epilepsy or other genetic diseases
  2. changes in drugs or in any intervention during the study
  3. Presence of cardiac disease including coronary artery disease, congestive heart failure, or uncontrolled hypertension per medical history
  4. Airway instability, tracheal surgery, or tracheal stenosis per medical history.
  5. History of drug or alcohol abuse
  6. Central nervous system masses or hydrocephalus per medical history
04

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    ketamine and dexmedetomidine group

    intranasal ketamine and dexmedetomidine was treated in the children

    Drug: ketamine and dexmedetomidine

  • Experimental
    ketamine group

    intranasal ketamine was treated in the children

    Drug: ketamine

  • Placebo comparator
    control group

    intranasal insaline was used in the children

    Drug: Saline

Interventions

  • Drugketamine and dexmedetomidine

    intranasal ketamine and dexmedetomidine for treatment for autism spectrum disorder

    Also known as: intranasal ketamine and dexmedetomidine

  • Drugketamine

    intranasal ketamine for treatment for autism spectrum disorder

    Also known as: intranasal ketamine

  • DrugSaline

    intranasal saline for treatment for autism spectrum disorder

    Also known as: intranasal saline

05

What researchers measure

Primary outcomes

  1. Autism Diagnostic Interview Revised (ADI-R)

    The Autism Diagnostic Interview Revised is an investigator-based semi-structured diagnostic interview, The ADI-R provides empirically derived diagnostic algorithms for three subdomains of qualitative impairments. The social interaction domain includes questions about emotional sharing, offering and seeking comfort, social smiling, and social responding comprising four subscores. The second domain (communication) assesses stereotyped expressions, pronoun reversal, and the social usage of language (B1-B4). In the third domain repetitive and stereotyped behavior as hand- and finger mannerisms, unusual sensory interest or activities are investigated by four subscales. Most items are scored from zero to three, relying on the interviewer to make judgements on child's behaviour based on the recall of information from parents/carers. . A total score is then calculated for each of the three subdomains. The ADI-R has an algorithm for autism based on scores in these three areas and on onset.

    Time frame: change from baseline at 2, 5 and 12 weeks

  2. Autism Diagnostic Observation Schedule (ADOS)

    The Autism Diagnostic Observation Schedule (ADOS) is a semi-structured assessment of communication, social interaction and play or imaginative use of materials for individuals suspected of having autism or other ASD. It consists of four modules, each of which is appropriate for children, adolescents and adults of differing developmental and language levels, ranging from no expressive or receptive language to verbally fluent adults. The examiner selects the module that is most appropriate for a particular child, adolescent on the basis of his/her expressive language level and chronological age. Selected algorithm items relating to social interaction and communication are then entered into an algorithm. The scores must meet the separate cut-offs for both the communication and social domains and the cut-off for the summation of the two. Repetitive behaviours are recorded and coded as part of the clinical observations but do not contribute to the ADOS summary algorithm.

    Time frame: change from baseline at 2, 5 and 12 weeks

Secondary outcomes

  1. autism behavior checklist (ABC)

    ABC is a scale used for nonadaptive behaviors created to screen and indicate the probability of a diagnosis of autism. The questionnaire approaches 57 atypical behaviors related to five areas: sensorial, relational, use of body and objects, and social skills. Scales\> 67 was diagnosised ASD, compare the change in scales in different time point(from baseline to endpoint)

    Time frame: change from baseline at 2, 5 and 12 weeks

  2. magnetic resonance spectroscopy(MRS)

    compare the metabolite concentrations and ratios in brain from Baseline to Endpoint (NAA,Glu,Gln,Cho,Cr,mI)

    Time frame: change from baseline at 5 and 12 weeks

  3. Childhood Autism Rating Scale (CARS)

    CARS assesses the child on a scale from 1 to 4 in each of 15 dimensions or symptoms (including the ability to relate to people, emotional response, imitation, body use, object use, listening response, fear or nervousness, verbal communication, nonverbal communication, activity level, level and reliability of intellectual response, adaptation to changes, visual response, taste, smell and touch responses and general impressions). A total score of at least 30 strongly suggests the presence of autism. Children who score between 30 and 36 have mild-to-moderate autism while those with scores between 37 and 60 have severe autism. Change in CARS from Baseline to Endpoint.

    Time frame: change from baseline at 2, 5 and 12 weeks

06

Study locations

1 site
  • Guangzhou Women and Children Medical Center
    Guangzhou, Guangdong 510000, China
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03434366
Lead sponsor
Guangzhou Women and Children's Medical Center
Responsible party
Ying Jun She, MD (Department of Anesthesiology, Guangzhou Women and Children's Medical Center) — Principal investigator
First posted
Feb 15, 2018
Start date
Jan 20, 2018
Primary completion
Dec 30, 2023 (estimated)
Completion
Dec 30, 2023 (estimated)
Last update
Apr 12, 2022

Study contacts

Qing Zhao, Doctor
principal investigator · Guangzhou Women and Children's Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion